408 related articles for article (PubMed ID: 31300270)
21. Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report.
Takemoto K; Miyahara N; Chikuie N; Hamamoto T; Ishino T; Ueda T; Takeno S
Auris Nasus Larynx; 2019 Oct; 46(5):813-817. PubMed ID: 30442438
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab in squamous cell carcinoma of the head and neck.
Specenier P
Expert Rev Anticancer Ther; 2018 May; 18(5):409-420. PubMed ID: 29560755
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
Przybylski K; Majchrzak E; Weselik L; Golusiński W
Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
[TBL] [Abstract][Full Text] [Related]
24. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
25. Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents.
Abraham P; Kish JK; Korytowsky B; Radtchenko J; Singh P; Shaw J; Feinberg B
J Med Econ; 2020 Feb; 23(2):125-131. PubMed ID: 31581922
[No Abstract] [Full Text] [Related]
26. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
27. Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy.
Daste A; De-Mones E; Cochin V; Dupin C; Digue L; Ravaud A; Domblides C
Oral Oncol; 2018 Jun; 81():116-118. PubMed ID: 29703607
[No Abstract] [Full Text] [Related]
28. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
29. Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer.
Yasumatsu R; Wakasaki T; Hashimoto K; Nakashima K; Manako T; Taura M; Matsuo M; Nakagawa T
Head Neck; 2019 Aug; 41(8):2610-2618. PubMed ID: 30835919
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
Reverdy T; Varnier R; de Talhouët S; Duplomb S; Bruyas A
Oral Oncol; 2023 Oct; 145():106533. PubMed ID: 37562096
[TBL] [Abstract][Full Text] [Related]
31. Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
Chikuie N; Hamamoto T; Ueda T; Taruya T; Kono T; Furuie H; Ishino T; Takeno S
Acta Med Okayama; 2021 Jun; 75(3):335-343. PubMed ID: 34176937
[TBL] [Abstract][Full Text] [Related]
32. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab.
Ueda T; Chikuie N; Takumida M; Furuie H; Kono T; Taruya T; Hamamoto T; Hattori M; Ishino T; Takeno S
Acta Otolaryngol; 2020 Feb; 140(2):181-187. PubMed ID: 31825711
[No Abstract] [Full Text] [Related]
33. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Cocks K; Contente M; Simpson S; DeRosa M; Taylor FC; Shaw JW
Pharmacoeconomics; 2019 Aug; 37(8):1041-1047. PubMed ID: 30972702
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
[TBL] [Abstract][Full Text] [Related]
36. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
37. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].
Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H
Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992
[TBL] [Abstract][Full Text] [Related]
38. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
Lv JW; Li JY; Luo LN; Wang ZX; Chen YP
J Immunother Cancer; 2019 Jun; 7(1):159. PubMed ID: 31238988
[TBL] [Abstract][Full Text] [Related]
39. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Desilets A; Soulières D
Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
[TBL] [Abstract][Full Text] [Related]
40. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]